Posters

      In vitro systems toxicology approach to investigate the effects of repeated cigarette smoke exposure on respiratory tract tissue cultures

      Mathis, C.; Kostadinova, R.; Wagner, S.; Frentzel, S.; Talamo, F.; Ivanov, N.; Xiang, Y.; Sewer, A.; Martin, F.; Peitsch, M. C.; Hoeng, J.
      Conference date
      Apr 28, 2013
      Conference name

      Systems Toxicology 2013 - From Basic Research to Human Risk Assessment
      Link to more information
      Topic
      Summary

      Objective: The aim of this study is to develop assay systems that model in vitro the impact of Cigarette Smoke (CS) on different human organotypic respiratory tract tissue cultures (bronchial, nasal, buccal and gingival) which are in contact with CS upon inhalation in vivo. Such assay systems may have a role in the assessment of potential modified risk tobacco products. Methods: We intended to mimic the smoking behavior of a moderate smoker during one day by exposing repeatedly and in parallel four tissue cultures (bronchial, nasal, buccal and gingival) directly at the air/liquid interface (Vitrocell® System) to four cigarettes with one hour intervals between each cigarette. These organotypic cultures are generated from primary cells derived from non-smoking donors and contain fibroblasts and epithelial cells in order to reproduce as closely as possible the in vivo situation. Results: Firstly, we simultaneously exposed all tissues to various CS concentrations ranging from 8% to 35% (diluted Vol/Vol with humidified air) or to humidified air (control). We found that gingival tissue was more sensitive to CS exposure than the other tissues based on cell viability assay. Secondly, all tissues were exposed in parallel to two doses of whole CS (10% and 16% - doses inducing less than 20% cell death) or to humidified air and various endpoints (e.g., gene and microrna expression, CYP activity, pro-inflammatory markers release, differential cell counts, cytotoxicity measurement) were captured at different post-exposure times. Conclusion: The systems biology endpoints obtained were analyzed using computational approaches. This allowed the identification of biological perturbations similar to those seen in vivo in smokers. This suggests that these four human in vitro tissue cultures when exposed to whole CS may be valuable models which could be used to investigate the impact of CS on the respiratory tract. 

      Related Publications

      Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products

      Systems Toxicology

      An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

      Systems Toxicology

      Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses

      Systems Toxicology

      Quantitative Modeling of In Vitro Data Using an Adverse Outcome Pathway for the Risk Assessment of Decreased Lung Function in Humans

      Systems Toxicology

      Systems toxicology: The future of risk assessment

      Systems Toxicology

      Systems biology: Methods and applications

      Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.